Contrary to popular belief, low-cost, low-value health services cost nearly double the amount of high-cost, low-value health services.
Low-cost, low-value health services contribute the most to unnecessary health spending in the United States and ultimately cost nearly twice as much as high-cost, low-value health service, according to a new study published in Health Affairs.
Low-value care has been characterized as health services that provide no net health benefit in specific clinical scenarios. While there has been previous research on the issue, spending on these health services still prevail.
“While many studies have focused on high-cost, low-value services, such as arthroscopic knee surgery for osteoarthritis, few have examined which low-value services contribute the most unnecessary costs,” wrote the authors.
The study analyzed data from the Virginia All Player Database in 2014, which included 5.5 beneficiaries of Medicare, Medicare Advantage, Medicaid, and private commercial insurers. The authors, which included co-Editor-in-Chief of The American Journal of Managed Care® A. Mark Fendrick, MD, assessed 44 services commonly deemed low-value. Each of the 44 services were categorized by cost into 4 groups: very low-cost, low-cost, high-cost, and very high-cost.
During that year, those 44 services were performed 5.4 million times. Using an algorithm that determined whether a service was high value or low value, the authors found that 1.7 million of the services performed were deemed low-value and 3.7 million were deemed high-value. Of the 1.7 million low-value services, 1.6 million were low- or very low-cost. Only 119,000 were high- or very high-cost.
The total cost of the low-cost and very-low cost, low-value services ($381 million) was almost double that of high-cost and very high-cost, low-value services ($205 million). With a total of $586 million, $9.90 was spent per beneficiary per month. This accounted for 2.1% of Virginia’s health care costs.
According to the authors, their findings should provide strong incentive for policy makers, healthcare systems, and clinicians to implement better ways to reduce unnecessary costs, without reducing the quality or access of care.
“Shared, nonpartisan health policy goals are to improve quality of care, enhance patient experience, and lower healthcare costs in the United States,” wrote the authors.
A seemingly easy answer to this issue is to identify, measure, and reduce the use of low-value care, but it has been harder to bring the answer to fruition, according to the authors. This is because the value of a specific health service fluctuates based upon who receives the service, who provides it, and where it is provided.
While changing a physician’s practice pattern has proven to be difficult in the past, even a small decrease in the performance of low- and very low-cost low-value services would make a difference.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Blister Packs May Help Solve Medication Adherence Challenges and Lower Health Care Costs
June 10th 2025Julia Lucaci, PharmD, MS, of Becton, Dickinson and Company, discusses the benefits of blister packaging for chronic medications, advocating for payer incentives to boost medication adherence and improve health outcomes.
Listen
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
Many Patients Stop GLP-1s Before Reaching Target Dose: Hamlet Gasoyan, PhD
June 19th 2025Discontinuing the weight loss treatment before hitting the recommended maintenance dose contributes to low-value care despite provider follow-up and efforts to manage side effects, says Hamlet Gasoyan, PhD, Cleveland Clinic.
Read More